重组人血管内皮抑素联合化疗一线治疗上皮性卵巢癌的临床观察

目的观察重组人血管内皮抑素（恩度）联合一线化疗方案治疗上皮性卵巢癌的临床疗效和安全性。方法收集2010年8月～2012年8月的36例经病理组织学确诊的复发或转移性卵巢癌患者，分为试验组（重组人血管内皮抑素联合一线化疗，n=18）和对照组（单纯一线化疗，n=18）。试验组采用重组人血管内皮抑素15mg每日静滴第1。14天，联合各种一线化疗方案，对照组单纯进行一线化疗，两组均21d为1周期。结果试验组完全缓解（CR）6例，部分缓解（PR）6例，稳定（SD）4例，进展（PD）2例；对照组CR2例，PR5例，SD6例，PD5例。两组有效率（RR）分别为66．7％和38．9％，疾病控制率（DCR）分别为88．9％和72．2％，差异有统计学意义（P〈0．05）。中位疾病进展时间（TTP）试验组为7．5个月，对照组4．9个月，两组比较，差异有统计学意义（P=0．014）。两组血液学毒性和消化系统毒性差异无统计学意义（P〉0．05），试验组1～2级心律失常的发生率略高于对照组，但差异无统计学意义（11．8％vs5．9％，P〉0．05）。结论重组人血管内皮抑素联合一线化疗方案能明显提高复发转移性上皮催卵巢癌的RR和DCR，延长中位TTP，安全性良好，可以作为上皮性卵巢癌的一线治疗方案。

Clinical observation of recombinant human endostatin combined with chemotherapy in first-line treatment of epithelial ovarian cancer

Objective To observe the clinical efficacy and safety of recombinant human endostatin （endostar） combined with first-line chemotherapy in the treatment of epithelial ovarian cancer. Methods Thirty-six patients with recurrent or metastatic ovarian cancer diagnosed by histopathology from August 2010 to August 2012 were divided into the ex- perimental group （recombinant human endostation combined with first-line chemotherapy,n=18） and the control group （simple first-line chemotherapy,n=18）.The experimental group received the daily intravenous infusion of 15 mg of en- dostar from day 1 to day 14 combined with varieties of first-line chemotherapy;The control group received the simple first-line chemotherapy;Both groups had 21 days as a cycle. Results In the experimental group,6 patients had com- plete remission （CR）,6 patients had partical remission （PR）,4 patients had stable disease （SD） and 2 patients had pro gressive disease （PD）;In the control group,CR in 2 cases,PR in 5 cases,SD in 6 cases and PD in 5 cases.The response rates （RR） of the two groups were 66.7% and 38.9% respetively and the disease control rates （DCR） were 88.9% and 72.2% respectively,with statistically significant differences for both（P〈0.05）.The median time to progression （＇IYFP） was 7.5 months in the experimental group and 4.9 months in the control group,with statistically significant difference （P= 0.014）.The two groups were not statistically different in the hematological toxicity and digestive toxicity（P〉0.05）;The experimental group was higher than the control group in the incidence of grade 1-2 arrhythmias,with no statistically significant difference（P〉0.05）. Conclusion Recombinant human endostatin combined with first-line chemotherapy can significantly improve the response rate and disease control rate of recurrent metastatic epithelial ovarian cancer and prolong median TTP and shows good safety,thus can serve as the first-line treatment of epithelial ovarian cancer